Universal Cytomegalovirus Screening in the First Trimester of Pregnancy: The Multicentre Observational Cohort Study in the Area of Barcelona (CITEMB Study)

Altres autors/es

Institut Català de la Salut

[Sánchez-Durán MÁ] Unitat de Medicina Fetal, Servei d’Obstetrícia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Esperalba J] Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. [Scazzocchio E, Fernández-Torm I, Vázquez-Segura E] Atenció a la Salut Sexual i Reproductiva (ASSIR) Esquerra, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Gracia-Salazar O] Atenció a la Salut Sexual i Reproductiva (ASSIR) Muntanya, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Maiz N] Unitat de Medicina Fetal, Servei d’Obstetrícia, Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Data de publicació

2026-03-04T13:12:21Z

2026-03-04T13:12:21Z

2026-01-09



Resum

Congenital infection; Cytomegalovirus; Fetal medicine


Infecció congènita; Citomegalovirus; Medicina fetal


Infección congénita; Citomegalovirus; Medicina fetal


Objective To determine the CMV seroprevalence among pregnant women and assess the rate of primary CMV infections during the first trimester. Design Prospective multicentre observational cohort study. Setting Four primary care centres (ASSIRs) and two tertiary hospitals in Barcelona and its metropolitan area. Pupulation or Sample Pregnant women attending first-trimester antenatal visits between October 2022 and September 2024. Methods All participants underwent CMV IgG and IgM serological testing at the first antenatal visit. Women with positive IgM and low or intermediate IgG avidity were diagnosed with primary CMV infection and managed according to local protocols, including treatment with valaciclovir and fetal follow-up. Main Outcome Measures CMV screening acceptance rate, seroprevalence, rate of primary infection, fetal infection, and neonatal outcomes up to one year of age. Results Of 3 677 pregnant women recruited, 3 357 were included in the final analysis. CMV screening acceptance was high. Seroprevalence was 77.7% (95% CI 76.2%–79.1%), and 743 women (22.1%, 95% CI 20.7%–23.6%) were seronegative. Five cases (0.15%, 95% CI 0.05%–0.37%) of primary CMV infection were identified and treated. No fetal infections were detected by amniocentesis. One newborn tested positive for CMV but remained asymptomatic at birth and at 6 months. Women who were seronegative were generally older, of European origin, and had higher education and employment rates. Conclusions Universal first-trimester CMV screening is feasible and well accepted in a public healthcare setting. While the rate of primary infection was low, early identification of seronegative women offers opportunities for preventive counselling and targeted follow-up.


This work was supported by the Generalitat de Catalunya, Departament de Salut, through the Pla Estrategic de Recerca i Innovació en Salut (PERIS), grant number SLT021/21/000051. The grant did not include external peer review for scientific quality. The funder had no role in the conduct of the research or the writing of the manuscript.

Tipus de document

Article


Versió publicada

Llengua

Anglès

Publicat per

Wiley

Documents relacionats

BJOG: An International Journal of Obstetrics & Gynaecology;

https://doi.org/10.1111/1471-0528.70137

info:eu-repo/grantAgreement/ES/PERIS2016-2020/SLT021%2F21%2F000051

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

Aquest element apareix en la col·lecció o col·leccions següent(s)